iX Biopharma

iX Biopharma is a listed, specialty pharmaceutical and nutraceutical company focusing on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent-protected formulations for sublingual delivery. iX Biopharmas pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharmas drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia. iX Biopharma has developed Xativa, the worlds first freeze-dried sublingual medicinal cannabis wafer. The Groups nutraceuticals division, Entity Health Limited, is engaged in the development and commercialisation of nutraceutical...

Patented sublingual drug delivery technology,novel drug delivery systems,pain management,and therapies for diseases of the central nervous system

Ix biopharma operates in the Pharmaceutical manufacturing industry.

Ix biopharma's revenue is 1m - 10m

Ix biopharma has 11 - 50 employees.